ZURICH, Switzerland — Wallstreet-Billionaire.com is an AI trading simulator, designed to help traders become profitable, find their edge, avoid losing trades and focus on profitable patterns.
Routine, practice and know-how are essential in trading. WallStreet-Billionaire.com analyzed thousands of demo trades done with the instant feedback free demo trading tool revealing retail traders main weaknesses.
“Most retail traders fail because they try to force trading strategies that do not fit their personality or skills,” said a spokesperson for Wallstreet-Billionaire.com. “Trading is a highly competitive business and needs a lot of practice, routine and understanding of own intrinsic action patterns. Retail traders lack the routine and the knowledge of the own edge.». On WallStreet-Billionaire.com traders place dozens of trades in just minutes, get instant profit/loss results and get advice from an AI Coach. Additionally the trade replay videos help traders understand how they traded compared to the best possible way of trading this chart. The TradeVision AI can furthermore select real market underlyings where the chart match the traders profitable trade setups. Perfections needs practice.».
Realistic Market Practice: Traders execute paper trades against 600.000 real charts with instant profit and loss (P&L) feedback. The trade replay sheds light on the traders past actions and how to optimize the trades for higher profitability or avoidance of losses..
Trade Replay: The trade replay sheds light on the traders past actions and how to optimize the trades for higher profitability or avoidance of losses..
Personalized AI Trading Coach: An integrated AI mentor analyzes trade management, identifies costly mistakes, and suggestions for trade configurations.
Performance Analytics: Comprehensive statistics quantify the trader’s approach and extrapolate whether or not this trading style can be profitable over a longer period of time.
TradeVision AI: After completing 100 free simulated trades, the AI identifies the precise technical setups where the trader naturally excels and suggests matching charts in the real markets.
The trading simulator is 100% free to start and accessible immediately in any browser without requiring downloads or credit cards.
Developed by inside finance GmbH in Switzerland, Wallstreet-Billionaire.com is an AI training platform for traders. By integrating realistic chart simulation, performance tracking, and AI-driven coaching, the platform empowers retail investors to discover their abilities, refine high-probability trading patterns, and find real market trades matching their profitable trade patterns.
Dallas, United States, August 31st, 2026, FinanceWire
Disseminated on behalf of Lake Victoria Gold
As gold prices held near record levels through the first half of 2026, investor attention has increasingly turned to a key question in the mining sector: which developers are closest to transitioning from permitted deposits to producing mines. Lake Victoria Gold (TSXV: LVG) (OTCQB: LVGLF) (FSE: E1K) has cleared a sequence of milestones on its Imwelo project in Tanzania that position the company at that threshold.
The Imwelo project holds Mining Licence ML 538/2015 and is fully permitted. A 23-hole, 1,136-metre sterilization drilling program completed in June confirmed that the plant and accommodation footprints are clear of mineralization. On June 29, 2026, the Tanzania Mining Commission approved a Tanzanian-led EPCM (Engineering, Procurement, and Construction Management) structure for the project, with City Engineering Company Ltd. serving as primary contractor and Sutton Consulting International providing international technical support; Senior Project Manager Charl Coetzee mobilized to site on July 8, 2026. On the financing side, the company entered into a binding term sheet on April 1, 2026 for a gold loan of up to 6,000 ounces, approximately US$25 million from Monetary Metals, to be repaid in gold ounces rather than cash, and closed the final tranche of a convertible debenture financing on July 2, 2026, bringing that raise to $4,165,200. Construction start is targeted for the current quarter.
Markets have historically applied deep discounts to development-stage mining companies to reflect the execution risks associated with permitting, financing, construction, and commissioning. As those risks are retired, companies have often seen valuations shift from a developer’s discount toward a producer’s multiple. G Mining Ventures (TSX: GMIN) (OTCQX: GMINF) offers a recent example, having built the Tocantinzinho mine in Brazil on time and on budget, poured first gold in 2024, and produced 171,871 ounces generating approximately $580 million in revenue in its first full year of commercial production in 2025. Lundin Gold (TSX: LUG) (OTCQX: LUGDF) acquired the Fruta del Norte deposit in Ecuador for $240 million in 2014, reached commercial production in 2020, produced 498,315 ounces in 2025, and now carries a market value in the C$20 billion range. Montage Gold (TSX: MAU) (OTCQX: MAUTF) is undergoing the same transition, with its fully funded, $825 million Koné project in Côte d’Ivoire advancing ahead of schedule and first gold now targeted for the fourth quarter of 2026. TRX Gold (NYSE American: TRX) (TSX: TRX) is demonstrating the same trajectory within Tanzania itself: its Buckreef mine, located in the same Geita greenstone belt as Imwelo, produced 7,426 ounces last quarter at a record average realized price of $4,703 per ounce. Barrick holds an equity position in Lake Victoria Gold, Tanzania’s Taifa Group is contracted for civil works and contract mining, and management, directors, and strategic partners collectively hold more than 60% of shares outstanding.
Imwelo has been the subject of JORC-code Preliminary Economic Assessment and pre-feasibility work; however, these studies are not current under NI 43-101, and the company has not completed a feasibility study establishing mineral reserves under CIM Definition Standards. Any decision to commence production is not based on a feasibility study of mineral reserves and carries an increased risk of economic or technical failure.
Lake Victoria Gold is a rapidly growing gold exploration and development company listed on the TSX Venture Exchange under the symbol LVG. Leveraging our unique position and experience, the Company is principally focused on growth and consolidation in the highly prolific and prospective Lake Victoria Goldfield in Tanzania. The Company has a 100% interest in the Tembo project which has over fifty thousand meters of drilling and is located adjacent to Barrick’s Bulyanhulu Mine. The Company also holds a 100% interest in the Imwelo Project which is a fully permitted gold project west of AngloGold Ashanti’s Geita Gold Mine. With historical resource estimates and a JORC Compliant 2021 pre-feasibility study, the project is fully permitted for mine construction and production, positioning it as a near-term development opportunity. LVG has assembled a highly experienced team with a track record of developing, financing, and operating mining projects in Africa with management, directors and partners owning more than 60% of the shares. Notably, the Company is grateful for the validation that comes with the support and equity investment from Barrick and strategic partnership with Taifa Group. Taifa Group (a diverse group of companies with interests in amongst others, Mining, Telecoms, Oil & Gas, Agri Business, Pharmaceuticals and Leather) has entered into an agreement with the Company to obtain an equity stake in the Company and through its wholly owned subsidiary Taifa Mining (a wholly Tanzanian owned company), or other nominees. Taifa Mining will also conduct all the contract mining and civil works for the Imwelo project. Taifa Mining is Tanzania’s largest mining contractor with over 30 years mining related experience. Taifa have been the contractor of choice to most mines in Tanzania and have maintained long and successful relationships with companies such as Petra, De Beers, Barrick, and AngloGold Ashanti. In addition, Taifa also owns the largest fleet of mining equipment in Tanzania. As a company, Taifa is committed to adopting and adhering to the latest internationally recognized standards throughout all aspects of its business.
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the timing of construction, financing, and project development. Such statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements.
NOTE TO INVESTORS:WallStreetPR is a financial news and publishing company that maximizes investor awareness for public and private businesses. Its core mission is to empower individuals by creating a highly connected, well-informed investor community. For more information, please visit https://wallstreetpr.com. Please see full terms of use and disclaimers on the WallstreetPR website applicable to all content provided by WallstreetPR, wherever published or re-published: https://wallstreetpr.com/disclaimer/. Please note that Akchirpy Media LLP has been compensated two thousand dollars for distributing this content on behalf of EDM Media LLC.
Dallas, United States, August 31st, 2026, FinanceWire
Disseminated on behalf of Lake Victoria Gold
As gold prices held near record levels through the first half of 2026, investor attention has increasingly turned to a key question in the mining sector: which developers are closest to transitioning from permitted deposits to producing mines. Lake Victoria Gold (TSXV: LVG) (OTCQB: LVGLF) (FSE: E1K) has cleared a sequence of milestones on its Imwelo project in Tanzania that position the company at that threshold.
The Imwelo project holds Mining Licence ML 538/2015 and is fully permitted. A 23-hole, 1,136-metre sterilization drilling program completed in June confirmed that the plant and accommodation footprints are clear of mineralization. On June 29, 2026, the Tanzania Mining Commission approved a Tanzanian-led EPCM (Engineering, Procurement, and Construction Management) structure for the project, with City Engineering Company Ltd. serving as primary contractor and Sutton Consulting International providing international technical support; Senior Project Manager Charl Coetzee mobilized to site on July 8, 2026. On the financing side, the company entered into a binding term sheet on April 1, 2026 for a gold loan of up to 6,000 ounces, approximately US$25 million from Monetary Metals, to be repaid in gold ounces rather than cash, and closed the final tranche of a convertible debenture financing on July 2, 2026, bringing that raise to $4,165,200. Construction start is targeted for the current quarter.
Markets have historically applied deep discounts to development-stage mining companies to reflect the execution risks associated with permitting, financing, construction, and commissioning. As those risks are retired, companies have often seen valuations shift from a developer’s discount toward a producer’s multiple. G Mining Ventures (TSX: GMIN) (OTCQX: GMINF) offers a recent example, having built the Tocantinzinho mine in Brazil on time and on budget, poured first gold in 2024, and produced 171,871 ounces generating approximately $580 million in revenue in its first full year of commercial production in 2025. Lundin Gold (TSX: LUG) (OTCQX: LUGDF) acquired the Fruta del Norte deposit in Ecuador for $240 million in 2014, reached commercial production in 2020, produced 498,315 ounces in 2025, and now carries a market value in the C$20 billion range. Montage Gold (TSX: MAU) (OTCQX: MAUTF) is undergoing the same transition, with its fully funded, $825 million Koné project in Côte d’Ivoire advancing ahead of schedule and first gold now targeted for the fourth quarter of 2026. TRX Gold (NYSE American: TRX) (TSX: TRX) is demonstrating the same trajectory within Tanzania itself: its Buckreef mine, located in the same Geita greenstone belt as Imwelo, produced 7,426 ounces last quarter at a record average realized price of $4,703 per ounce. Barrick holds an equity position in Lake Victoria Gold, Tanzania’s Taifa Group is contracted for civil works and contract mining, and management, directors, and strategic partners collectively hold more than 60% of shares outstanding.
Imwelo has been the subject of JORC-code Preliminary Economic Assessment and pre-feasibility work; however, these studies are not current under NI 43-101, and the company has not completed a feasibility study establishing mineral reserves under CIM Definition Standards. Any decision to commence production is not based on a feasibility study of mineral reserves and carries an increased risk of economic or technical failure.
Lake Victoria Gold is a rapidly growing gold exploration and development company listed on the TSX Venture Exchange under the symbol LVG. Leveraging our unique position and experience, the Company is principally focused on growth and consolidation in the highly prolific and prospective Lake Victoria Goldfield in Tanzania. The Company has a 100% interest in the Tembo project which has over fifty thousand meters of drilling and is located adjacent to Barrick’s Bulyanhulu Mine. The Company also holds a 100% interest in the Imwelo Project which is a fully permitted gold project west of AngloGold Ashanti’s Geita Gold Mine. With historical resource estimates and a JORC Compliant 2021 pre-feasibility study, the project is fully permitted for mine construction and production, positioning it as a near-term development opportunity. LVG has assembled a highly experienced team with a track record of developing, financing, and operating mining projects in Africa with management, directors and partners owning more than 60% of the shares. Notably, the Company is grateful for the validation that comes with the support and equity investment from Barrick and strategic partnership with Taifa Group. Taifa Group (a diverse group of companies with interests in amongst others, Mining, Telecoms, Oil & Gas, Agri Business, Pharmaceuticals and Leather) has entered into an agreement with the Company to obtain an equity stake in the Company and through its wholly owned subsidiary Taifa Mining (a wholly Tanzanian owned company), or other nominees. Taifa Mining will also conduct all the contract mining and civil works for the Imwelo project. Taifa Mining is Tanzania’s largest mining contractor with over 30 years mining related experience. Taifa have been the contractor of choice to most mines in Tanzania and have maintained long and successful relationships with companies such as Petra, De Beers, Barrick, and AngloGold Ashanti. In addition, Taifa also owns the largest fleet of mining equipment in Tanzania. As a company, Taifa is committed to adopting and adhering to the latest internationally recognized standards throughout all aspects of its business.
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the timing of construction, financing, and project development. Such statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements.
NOTE TO INVESTORS:WallStreetPR is a financial news and publishing company that maximizes investor awareness for public and private businesses. Its core mission is to empower individuals by creating a highly connected, well-informed investor community. For more information, please visit https://wallstreetpr.com. Please see full terms of use and disclaimers on the WallstreetPR website applicable to all content provided by WallstreetPR, wherever published or re-published: https://wallstreetpr.com/disclaimer/. Please note that Akchirpy Media LLP has been compensated two thousand dollars for distributing this content on behalf of EDM Media LLC.
New York, United States, August 31st, 2026, FinanceWire
EdWealth (edwealth.ai) today announced the publication of MoneyBench, a benchmark developed by the company to evaluate how AI systems answer personal finance questions. The benchmark compares Ed, EdWealth’s AI personal finance coach, with ChatGPT and Gemini on usefulness and factual accuracy.
Ask an AI about money and a confident, plausible answer arrives instantly. Whether the numbers are right is invisible as you read. In an Intuit Credit Karma survey, 52% of adults who acted on AI financial advice reported a poor decision [1].
According to EdWealth’s MoneyBench results for July, Ed ranked first, winning 62.3% of questions, compared with 20.8% for Gemini and 17.0% for ChatGPT [2].
What made the difference
Writing quality did not separate the three, and accuracy scores often matched. Usefulness did: Ed averaged 4.24 on a five-point scale to ChatGPT’s 3.62 and Gemini’s 3.47, higher on roughly seven of ten questions against each.
Five things set Ed apart:
Live numbers. Ed’s 120-plus financial data-and-analysis tools query the current filing, live price, holdings table, not last quarter’s memory.
Decision-first answers. Conclusion first, then reasoning, then options.
Fact and interpretation, separated. Limits and deadlines are stated as rules, context and trade-offs as interpretation. Most AI blurs the two.
A coach that stays. From what a user shares, Ed learns their numbers, goals and habits; every answer builds on the last, across cash flow, taxes, stock compensation, funds, insurance. Account connections are read-only.
Statute, not guesswork. Phase-outs, benefit formulas and multi-year tax rules come from a base of 11,566 parameters, sourced to the IRS, SSA, CMS and state authorities, across 51 US jurisdictions.
Confidence is not correctness
“Wealthy families always had a money person to call. Everyone else got search results, then a confident chatbot,” said Allen Ng, founder of EdWealth. “Ed closes that gap: live numbers, the reasoning shown, the decision still yours.”
The answers were scored by Claude, an AI from Anthropic, which builds none of the three. It checked each answer’s key figures against live sources, and an answer containing a fact proven false could not win. That check cost Ed: its score fell 5.3 points, both competitors rose, and Ed still finished first. Its 40 losses appear in the paper beside the wins. Where Ed’s facts were wrong, its usefulness fell with them: useful answers are built on correct ones.
In May’s first round Ed placed third of three, held back by weak data retrieval. EdWealth rebuilt it, and Ed has led every round since.
The part no benchmark can measure
The same question has a different right answer for each person: holdings, taxes, goals. A general assistant answers for everyone; Ed answers for one person, and keeps learning them. The test could not see that: standalone questions, nothing known about the asker. A benchmark measures the answer; a money person of your own knows the question behind it.
“We put our product on trial in public,” said Ng. “Financial AI should be judged on one question: does it help a person make a better money decision. Useful, and right. Only then does the rest follow. Money at peace, wealth in motion.”
About EdWealth
EdWealth builds agentic AI products for personal financial clarity and Financial Fitness. Its debut product, Ed, is a personal finance coach for modern households; user data is never for sale. Ed is available at edwealth.ai, on the App Store, and on Google Play.
Disclaimer: Ed provides financial information and education only — not investment, tax, or legal advice, and not a recommendation to buy or sell anything. Ed does not provide personalised investment recommendations. Ed is not a licensed financial adviser; its AI-generated outputs may be wrong, and all decisions are your own. Consult a licensed professional before acting. Availability, features, and pricing may vary by jurisdiction; Ed is offered only where permitted by applicable law.
Sources: [1] Intuit Credit Karma, survey of 1,019 US adults, fielded August 7-14, 2025. [2] Systems as tested, July 2026: Ed in production configuration; ChatGPT (GPT-5.6 Sol) at Pro effort; Gemini (3.6 Flash) at default configuration.
Contact
Communications Lead Phoebe Woo EdWealth info@edwealth.ai
Raleigh, United States, August 31st, 2026, FinanceWire
Executes a major step in RedHill’s strategic roadmap to fundamentally reposition the Company’s commercial business toward new and larger product opportunities, revenue growth and an accelerated path toward operational profitability
—
Realizes substantial value from RedHill’s 70% stake in Talicia,currently held within a shared ownership and economic structure, while immediately creating a stronger liquidity position and fully funding the next major steps in RedHill’s transformational commercial expansion
—
Under the terms of the agreement, Apotex will pay RedHill an upfront payment of $18 million plus up to an additional $35 million in potential worldwide net sales milestone payments
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced the divestment of its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) (“Apotex”) for an upfront payment of $18 million plus up to an additional $35 million in potential payments based on worldwide net sales milestones.
“This transaction is a pivotal milestone for RedHill. We are converting our 70% stake in Talicia into immediate capital, significantly stronger liquidity and meaningful potential upside, while fully funding the next major step in our commercial business expansion. I want to thank the RedHill team for developing and positioning this important product for success, targeting H. pylori infection, the main cause of gastric cancer and stomach ulcers,” said Dror Ben-Asher, RedHill’s Chief Executive Officer. “We are confident that given its proven capabilities, Apotex is the right home to grow Talicia globally. We thank Apotex for their partnership on the successful conclusion of this transaction, which unlocks the resources needed to scale RedHill’s existing gastrointestinal (GI) commercial franchise into a stronger and larger one, including new, high-value, FDA-approved product opportunities intended to drive sustained growth and accelerate our path toward operational profitability.”
Under the terms of the agreement, RedHill received $18 million in cash and has the potential to receive up to an additional $35 million in payments based on worldwide net sales milestones from Apotex. In return, Apotex will receive RedHill’s 70% interest in Talicia, following Apotex’s prior acquisition of Cumberland Pharmaceuticals Inc.’s U.S. branded business, which included Cumberland Pharmaceuticals Inc.’s 30% ownership in Talicia.
RedHill was advised by Morningstar Law Group and Greenberg Traurig LLP on this transaction.
About RedHill Biopharma
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill’s key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications with a track record of U.S. government and academic collaborations intended for medical countermeasure development including for EVD, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), an ongoing Phase 2 study in prostate cancer in combination with darolutamide and a Phase 2/3 program for hospitalized COVID-19; (ii) RHB-102 (Bekinda), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn’s disease (based on RHB-104’s positive Phase 3 Crohn’s disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases.
About Apotex
Apotex is a Canadian-based global health company. Apotex improves everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, Apotex is the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and include, among others, statements regarding the divestment of Talicia and the potential use of the proceeds of that sale; the Company’s ability to acquire or develop new products, expected revenue growth, the Company’s anticipated path toward operational profitability, and the Company’s strategic plans for its commercial business. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: the risk that the divestment of Talicia does not result in any planned asset acquisitions, or that any such acquisitions are not commercially successful; the risk that proceeds from the transaction are insufficient to fund the Company’s strategic plans or that such plans do not achieve the anticipated results; the risk that opaganib is not accepted into Ebola virus disease control programs, or if accepted, that it does not demonstrate efficacy; the risk that development of RHB-204 for Crohn’s disease may not be completed, or if completed may not be approved or may not achieve commercial success; the risk that opaganib is not effective against the indications for which we develop our products; the risk that RHB-102 (Bekinda) does not effectively reduce GLP-1/GIP-related nausea, vomiting and diarrhea; the risk regarding the Company’s ability to regain and maintain compliance with Nasdaq’s listing requirements, including the minimum bid price requirement; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that the Company will not receive future milestone payments under its existing agreements, including under the Apotex agreement, or that they will be less than anticipated; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company’s proposed development plans for its programs; the risk that the Company’s development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to establish and maintain corporate collaborations; (vi) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (vii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (viii) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (x) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xi) the Company’s ability to collect on its judgement against Kukbo; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company’s Expanded Access Program; (xiv) competition from other companies and technologies within the Company’s industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on April 27, 2026. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.
Contact
Chief Corporate & BD Officer Adi Frish RedHill Biopharma adi@redhillbio.com
New York, United States, August 31st, 2026, FinanceWire
EdWealth (edwealth.ai) today announced the publication of MoneyBench, a benchmark developed by the company to evaluate how AI systems answer personal finance questions. The benchmark compares Ed, EdWealth’s AI personal finance coach, with ChatGPT and Gemini on usefulness and factual accuracy.
Ask an AI about money and a confident, plausible answer arrives instantly. Whether the numbers are right is invisible as you read. In an Intuit Credit Karma survey, 52% of adults who acted on AI financial advice reported a poor decision [1].
According to EdWealth’s MoneyBench results for July, Ed ranked first, winning 62.3% of questions, compared with 20.8% for Gemini and 17.0% for ChatGPT [2].
What made the difference
Writing quality did not separate the three, and accuracy scores often matched. Usefulness did: Ed averaged 4.24 on a five-point scale to ChatGPT’s 3.62 and Gemini’s 3.47, higher on roughly seven of ten questions against each.
Five things set Ed apart:
Live numbers. Ed’s 120-plus financial data-and-analysis tools query the current filing, live price, holdings table, not last quarter’s memory.
Decision-first answers. Conclusion first, then reasoning, then options.
Fact and interpretation, separated. Limits and deadlines are stated as rules, context and trade-offs as interpretation. Most AI blurs the two.
A coach that stays. From what a user shares, Ed learns their numbers, goals and habits; every answer builds on the last, across cash flow, taxes, stock compensation, funds, insurance. Account connections are read-only.
Statute, not guesswork. Phase-outs, benefit formulas and multi-year tax rules come from a base of 11,566 parameters, sourced to the IRS, SSA, CMS and state authorities, across 51 US jurisdictions.
Confidence is not correctness
“Wealthy families always had a money person to call. Everyone else got search results, then a confident chatbot,” said Allen Ng, founder of EdWealth. “Ed closes that gap: live numbers, the reasoning shown, the decision still yours.”
The answers were scored by Claude, an AI from Anthropic, which builds none of the three. It checked each answer’s key figures against live sources, and an answer containing a fact proven false could not win. That check cost Ed: its score fell 5.3 points, both competitors rose, and Ed still finished first. Its 40 losses appear in the paper beside the wins. Where Ed’s facts were wrong, its usefulness fell with them: useful answers are built on correct ones.
In May’s first round Ed placed third of three, held back by weak data retrieval. EdWealth rebuilt it, and Ed has led every round since.
The part no benchmark can measure
The same question has a different right answer for each person: holdings, taxes, goals. A general assistant answers for everyone; Ed answers for one person, and keeps learning them. The test could not see that: standalone questions, nothing known about the asker. A benchmark measures the answer; a money person of your own knows the question behind it.
“We put our product on trial in public,” said Ng. “Financial AI should be judged on one question: does it help a person make a better money decision. Useful, and right. Only then does the rest follow. Money at peace, wealth in motion.”
About EdWealth
EdWealth builds agentic AI products for personal financial clarity and Financial Fitness. Its debut product, Ed, is a personal finance coach for modern households; user data is never for sale. Ed is available at edwealth.ai, on the App Store, and on Google Play.
Disclaimer: Ed provides financial information and education only — not investment, tax, or legal advice, and not a recommendation to buy or sell anything. Ed does not provide personalised investment recommendations. Ed is not a licensed financial adviser; its AI-generated outputs may be wrong, and all decisions are your own. Consult a licensed professional before acting. Availability, features, and pricing may vary by jurisdiction; Ed is offered only where permitted by applicable law.
Sources: [1] Intuit Credit Karma, survey of 1,019 US adults, fielded August 7-14, 2025. [2] Systems as tested, July 2026: Ed in production configuration; ChatGPT (GPT-5.6 Sol) at Pro effort; Gemini (3.6 Flash) at default configuration.
Contact
Communications Lead Phoebe Woo EdWealth info@edwealth.ai
Raleigh, United States, August 31st, 2026, FinanceWire
Executes a major step in RedHill’s strategic roadmap to fundamentally reposition the Company’s commercial business toward new and larger product opportunities, revenue growth and an accelerated path toward operational profitability
—
Realizes substantial value from RedHill’s 70% stake in Talicia,currently held within a shared ownership and economic structure, while immediately creating a stronger liquidity position and fully funding the next major steps in RedHill’s transformational commercial expansion
—
Under the terms of the agreement, Apotex will pay RedHill an upfront payment of $18 million plus up to an additional $35 million in potential worldwide net sales milestone payments
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced the divestment of its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) (“Apotex”) for an upfront payment of $18 million plus up to an additional $35 million in potential payments based on worldwide net sales milestones.
“This transaction is a pivotal milestone for RedHill. We are converting our 70% stake in Talicia into immediate capital, significantly stronger liquidity and meaningful potential upside, while fully funding the next major step in our commercial business expansion. I want to thank the RedHill team for developing and positioning this important product for success, targeting H. pylori infection, the main cause of gastric cancer and stomach ulcers,” said Dror Ben-Asher, RedHill’s Chief Executive Officer. “We are confident that given its proven capabilities, Apotex is the right home to grow Talicia globally. We thank Apotex for their partnership on the successful conclusion of this transaction, which unlocks the resources needed to scale RedHill’s existing gastrointestinal (GI) commercial franchise into a stronger and larger one, including new, high-value, FDA-approved product opportunities intended to drive sustained growth and accelerate our path toward operational profitability.”
Under the terms of the agreement, RedHill received $18 million in cash and has the potential to receive up to an additional $35 million in payments based on worldwide net sales milestones from Apotex. In return, Apotex will receive RedHill’s 70% interest in Talicia, following Apotex’s prior acquisition of Cumberland Pharmaceuticals Inc.’s U.S. branded business, which included Cumberland Pharmaceuticals Inc.’s 30% ownership in Talicia.
RedHill was advised by Morningstar Law Group and Greenberg Traurig LLP on this transaction.
About RedHill Biopharma
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill’s key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications with a track record of U.S. government and academic collaborations intended for medical countermeasure development including for EVD, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), an ongoing Phase 2 study in prostate cancer in combination with darolutamide and a Phase 2/3 program for hospitalized COVID-19; (ii) RHB-102 (Bekinda), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn’s disease (based on RHB-104’s positive Phase 3 Crohn’s disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases.
About Apotex
Apotex is a Canadian-based global health company. Apotex improves everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, Apotex is the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and include, among others, statements regarding the divestment of Talicia and the potential use of the proceeds of that sale; the Company’s ability to acquire or develop new products, expected revenue growth, the Company’s anticipated path toward operational profitability, and the Company’s strategic plans for its commercial business. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: the risk that the divestment of Talicia does not result in any planned asset acquisitions, or that any such acquisitions are not commercially successful; the risk that proceeds from the transaction are insufficient to fund the Company’s strategic plans or that such plans do not achieve the anticipated results; the risk that opaganib is not accepted into Ebola virus disease control programs, or if accepted, that it does not demonstrate efficacy; the risk that development of RHB-204 for Crohn’s disease may not be completed, or if completed may not be approved or may not achieve commercial success; the risk that opaganib is not effective against the indications for which we develop our products; the risk that RHB-102 (Bekinda) does not effectively reduce GLP-1/GIP-related nausea, vomiting and diarrhea; the risk regarding the Company’s ability to regain and maintain compliance with Nasdaq’s listing requirements, including the minimum bid price requirement; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that the Company will not receive future milestone payments under its existing agreements, including under the Apotex agreement, or that they will be less than anticipated; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company’s proposed development plans for its programs; the risk that the Company’s development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to establish and maintain corporate collaborations; (vi) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (vii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (viii) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (x) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xi) the Company’s ability to collect on its judgement against Kukbo; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company’s Expanded Access Program; (xiv) competition from other companies and technologies within the Company’s industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on April 27, 2026. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.
Contact
Chief Corporate & BD Officer Adi Frish RedHill Biopharma adi@redhillbio.com
MEXC, a pioneer in 0-fee digital asset trading, reports a sharp rise in Spot trading activity on the platform as BTC topped $80,000 and ETH and SOL reached near six-month highs. From August 20 to 22, the average daily Spot trading volume of BTC, ETH, SOL, and XRP increased by approximately 299% from the daily average recorded between August 1 and 17. Over the same period, the combined average daily trading volume of ETH, SOL, and XRP exceeded that of BTC. Compared with the BTC-dominated trading structure seen from August 1 to 17, activity on the platform spread noticeably across a broader range of major assets.
This shift in trading composition had already emerged on August 19. On that day, the combined trading share of ETH, SOL, and XRP rose from 30.5% a day earlier to 46.7%, an increase of 16.2 percentage points and the largest single-day gain in August. Their combined daily share subsequently remained above the 34.9% baseline recorded from August 1 to 17, indicating that trading interest in these three major assets had begun to rise before BTC broke above $80,000.
On August 25, when BTC topped $80,000, BTC Spot trading volume increased by approximately 164% from the August 1 to 17 daily average. ETH volume rose by 220%, while SOL and XRP each increased by approximately 500%. BTC remained an important market signal during this rally, but the increase in platform activity was not limited to BTC. Instead, multiple major assets became active at the same time.
The trend continued on August 27, when ETH and SOL climbed to nearly six-month highs. On MEXC, ETH Spot trading volume increased by 36.3% from the previous day, while SOL volume rose by 109.7%. Together, the two assets accounted for 46.4% of combined trading volume across the four assets, marking a new August high and making them the primary drivers of the day’s increase in trading activity.
As market sentiment strengthens, trading demand can rotate quickly across major assets, making trading costs and execution efficiency increasingly important for users seeking to respond to market movements. MEXC currently offers 0-fee trading on selected SOL Spot trading pairs and all XRP Spot trading pairs. Combined with deep liquidity, this enables users to navigate market rotations at lower cost and with greater efficiency while capturing more opportunities.
About MEXC
MEXC is the world’s fastest-growing cryptocurrency exchange, trusted by more than 40 million users across 170+ markets. Built on a user-first philosophy, MEXC offers industry-leading 0-fee trading and access to over 3,000 digital assets. As the Gateway to Infinite Opportunities, MEXC provides a single platform where users can easily trade cryptocurrencies alongside tokenized assets, including stocks, ETFs, commodities, and precious metals.
MEXC, a pioneer in 0-fee digital asset trading, reports a sharp rise in Spot trading activity on the platform as BTC topped $80,000 and ETH and SOL reached near six-month highs. From August 20 to 22, the average daily Spot trading volume of BTC, ETH, SOL, and XRP increased by approximately 299% from the daily average recorded between August 1 and 17. Over the same period, the combined average daily trading volume of ETH, SOL, and XRP exceeded that of BTC. Compared with the BTC-dominated trading structure seen from August 1 to 17, activity on the platform spread noticeably across a broader range of major assets.
This shift in trading composition had already emerged on August 19. On that day, the combined trading share of ETH, SOL, and XRP rose from 30.5% a day earlier to 46.7%, an increase of 16.2 percentage points and the largest single-day gain in August. Their combined daily share subsequently remained above the 34.9% baseline recorded from August 1 to 17, indicating that trading interest in these three major assets had begun to rise before BTC broke above $80,000.
On August 25, when BTC topped $80,000, BTC Spot trading volume increased by approximately 164% from the August 1 to 17 daily average. ETH volume rose by 220%, while SOL and XRP each increased by approximately 500%. BTC remained an important market signal during this rally, but the increase in platform activity was not limited to BTC. Instead, multiple major assets became active at the same time.
The trend continued on August 27, when ETH and SOL climbed to nearly six-month highs. On MEXC, ETH Spot trading volume increased by 36.3% from the previous day, while SOL volume rose by 109.7%. Together, the two assets accounted for 46.4% of combined trading volume across the four assets, marking a new August high and making them the primary drivers of the day’s increase in trading activity.
As market sentiment strengthens, trading demand can rotate quickly across major assets, making trading costs and execution efficiency increasingly important for users seeking to respond to market movements. MEXC currently offers 0-fee trading on selected SOL Spot trading pairs and all XRP Spot trading pairs. Combined with deep liquidity, this enables users to navigate market rotations at lower cost and with greater efficiency while capturing more opportunities.
About MEXC
MEXC is the world’s fastest-growing cryptocurrency exchange, trusted by more than 40 million users across 170+ markets. Built on a user-first philosophy, MEXC offers industry-leading 0-fee trading and access to over 3,000 digital assets. As the Gateway to Infinite Opportunities, MEXC provides a single platform where users can easily trade cryptocurrencies alongside tokenized assets, including stocks, ETFs, commodities, and precious metals.
I have paid for both. That is the only reason this piece exists.
Most comparisons of this kind are written by people who have used one option and are guessing about the other. I spent nine months with a digital marketing agency before joining 100x Engine at Imperfect Labs, and I have now been inside that program for over a year.
The two experiences are not slightly different. They are different in kind.
Quick context on me: I run an advisory practice. Fourteen years in. Not a creator, never wanted to be one. I went looking for help because referrals had stopped scaling and I had no other way to reach people who did not already know someone who knew me.
What Hiring an Agency Actually Looks Like
I paid Rs 70,000 a month. That is Rs 8.4 lakh a year, and I was at the lower end of the market. Most competent agencies in India charge between Rs 1 lakh and Rs 1.5 lakh a month, so Rs 12 to 18 lakh annually.
For that I got a content calendar, a monthly shoot, and about twelve posts a month produced for me.
The work was not bad. It was competent, on time, and professionally edited. The strategy deck they gave me in month one was genuinely thoughtful.
Here is what went wrong anyway.
It did not sound like me. A client mentioned it about four months in. He said my Instagram felt like a different person from the one he sat across from in meetings. That was not a small problem. In advisory work, the entire product is that people trust your judgment. Content that sounds like a marketing department actively worked against the thing I was trying to build.
I learned nothing. Nine months in, I understood Instagram exactly as well as I had on day one. I could not have written a hook. I could not have told you why one video worked and another did not. I was renting a capability, not developing one.
The growth was flat. I went from roughly 400 followers to about 2,900 in nine months. Not nothing, but not much for Rs 6.3 lakh spent. More importantly, almost none of it converted to anything. No inbound enquiries. No conversations that started because someone had watched my content.
When it ended, everything stopped. This is the part people underestimate. I paused the retainer to reassess. Within three weeks there was no content going out, because there was no mechanism for content to exist without them. I had spent Rs 6.3 lakh and owned nothing that survived the invoice stopping.
What 100x Engine Actually Looks Like
The first thing that struck me was the speed.
I expected an onboarding phase, the way the agency had a discovery phase. Instead I was recording video on day two. Profile work, bio, audio setup, everything else ran at the same time in the background.
Imperfect Labs calls these parallel journeys. Nothing waits for anything else. The reasoning is that you learn faster from your own bad footage than from any lesson about making good footage.
I found this stressful for about ten days and then understood why they do it.
What is actually in the program:
Component
What it means
Blue Ocean Strategy
Finding the angle in your field nobody has taken. Ongoing all year, not one call.
18 sessions across the year. Turn up, ask anything, bring a drink.
Weekly Viral Hour with Sanket
Every week. What is working on Instagram right now.
WhatsApp with a growth consultant
They message you first. You do not chase anyone.
Front Row Sessions
Live Q&As with industry leaders.
The Blue Ocean Strategy piece is the one I misunderstood going in. I assumed it was a niche-picking session at the start. It is not. Shivansh Garg and the team kept coming back to it all year, asking questions as my content produced actual data. My starting angle was generic. Where I ended up was much narrower and much better, and I would not have found it in one session.
The Viral Hour sessions with Sanket run weekly. He is behind over 1 billion organic views and Rs 25 crore in revenue across the brands he has worked on. The insights here are genuinely game changing. He covers what the platform is rewarding that week and breaks down specific videos that spread, explaining why. A recorded course cannot do that. Neither could my agency, who were working from a strategy document written nine months earlier.
The WhatsApp access works differently from what I expected. I assumed I would send questions and receive answers. What actually happens is the consultants message first. Your hook is describing instead of creating tension. Your last three posts used the same structure. This topic is moving in your space right now, here is an angle.
I never had to know the right question. With the agency, I had to know what to ask for, and I did not know enough to ask well.
The Numbers Side by Side
Agency
100x Engine
Annual cost
Rs 12L to Rs 18L
Rs 5.5L
Who makes the content
Their team
You, with guidance
Does it sound like you
Rarely
That is the point
What you learn
Nothing
The whole method
If you stop paying
Everything stops
Skills and audience stay
My growth in 9 months
400 to 2,900
Not applicable
My growth in 12 months
Not applicable
620 to 21,300
The cost comparison surprised people I explained this to. The assumption is that a program with direct founder access costs more than an agency retainer. It costs less than half of what a mid-tier agency charges for a year, and I already knew from experience what the agency year produced.
Done For You vs Done With You
This is the whole comparison compressed into one distinction.
An agency does it for you. That is the product. You hand over the problem and they hand back output. For a company selling a product, this makes complete sense. Nobody needs the CEO to personally understand Instagram hooks.
For an individual professional, it makes much less sense. Your credibility is the product. When someone else writes your credibility, it does not read as credible.
100x Engine does it with you. The positioning is yours because you built it. The instincts are yours because you developed them. If I left tomorrow, none of it disappears.
That is not a marketing line. It is the mechanical difference between the two models and it explains every other difference on the list.
Where the Agency Was Genuinely Better
Being fair about this.
It required nothing from me. Once a month I sat for a shoot and the rest happened without my involvement. During my busiest quarters, that was worth something real. 100x Engine requires two to three posts a week and there is no version where someone else does that for you.
The production quality was higher. Their editing was better than mine will ever be. My content looks like a professional filmed on a phone, because it is. Theirs looked polished.
There was no learning curve. I did not have to get comfortable on camera, which took me about six weeks in the program and was genuinely unpleasant.
If your goal is a presentable Instagram presence with minimal personal involvement, an agency delivers that. It just will not build you an audience that trusts you, because trust does not survive being outsourced.
What Actually Changed
Twelve months into 100x Engine I was at 21,300 followers, up from 620.
More importantly, inbound enquiries started arriving from people who had never met me. In fourteen years of practice that had never happened once. Two of them converted into engagements that between them covered the program fee several times over.
I have now renewed for a second year. That decision took me a week, because Rs 5.5 lakh is a real number and I do not spend it casually. What settled it was that I already knew what happens when I stop. I had tested that with the agency. Content stops, drift sets in, nothing compounds.
Which One Fits Which Situation
An agency makes sense if:
You are a company or brand rather than an individual
Your face and voice are not the product
You genuinely cannot commit any weekly time to content
Polish matters more to you than connection
100x Engine makes sense if:
Your credibility is the business
You have real expertise built over years
You can post two to three times a week even in bad weeks
You want to own what gets built rather than rent it
There is a version of this decision where both are wrong, incidentally. If you are early in your career and have not yet developed a point of view worth broadcasting, neither option helps. The agency will produce content about nothing and the program will keep asking you questions you cannot answer yet.
The Thing I Wish Someone Had Told Me Earlier
I spent Rs 6.3 lakh before I understood what I was actually buying.
The question is not which option is better. It is what you want to exist at the end of the year. An agency gives you twelve months of content. A done with you program gives you the ability to make content for the rest of your career, plus an audience that came to you because of how you think.
